Great Lakes Advisors LLC Invests $6.97 Million in Protagonist Therapeutics, Inc. $PTGX
Great Lakes Advisors LLC has acquired a new stake in Protagonist Therapeutics, Inc., purchasing 56,904 shares valued at approximately $6.98 million. This investment comes amidst significant institutional ownership of PTGX (98.63%) and generally favorable analyst sentiment, despite a recent downgrade by Zacks Research. Protagonist Therapeutics reported strong quarterly earnings with revenue up 3,746.8% year-over-year, though the stock has seen insider selling totaling $17.8 million in the last 90 days.
248,322 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Eagle Health Investments LP
Eagle Health Investments LP has acquired 248,322 shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) for approximately $30.44 million, making it their 8th largest position. Other institutional investors like BlackRock Inc. and Vanguard Group Inc. have also adjusted their holdings in PTGX. The article also notes recent insider selling by the CEO and a director, alongside several analyst upgrades and price target increases for Protagonist Therapeutics.
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics, Inc. reported granting inducement awards to two new employees on August 17, 2026, comprising options to purchase 5,675 shares and RSUs for 1,500 shares of common stock. These awards, with an option exercise price of $155.10, were made under the company's Amended and Restated Inducement Plan and vest over four years. This action aims to attract and retain talent in accordance with Nasdaq Marketplace Rule 5635(c)(4).
PTGX Maintained by BMO Capital -- Price Target Raised to $178
BMO Capital has maintained its 'Outperform' rating for Protagonist Therapeutics Inc (PTGX) and significantly raised its price target from $112.00 to $178.00. Despite this positive analyst sentiment, GuruFocus indicates PTGX is 76.8% overvalued with a GF Value™ of $87.75, and its GF Score™ of 47/100 highlights weaknesses in profitability, growth, and valuation. Insider activity shows net selling of $17.8 million, suggesting caution for investors.
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
BMO Capital Markets has increased its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $178 from $112, maintaining an "outperform" rating and implying a 14.76% upside. Despite some recent analyst downgrades, the stock holds a "Moderate Buy" consensus and an average target of $140.53. The company reported strong quarterly earnings of $2.29 EPS and $213.47 million in revenue, significantly exceeding estimates, although insiders have sold $17.8 million worth of stock recently.
BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178
BMO Capital has reiterated its Buy rating on Protagonist Therapeutics (PTGX.US) and increased its target price to $178. This reflects a positive outlook from the investment firm regarding the company's prospects.
Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift
Protagonist Therapeutics (PTGX) reported a significant swing to profitability in Q2 2026, with net income of US$162.85 million and diluted EPS of US$2.29, compared to a loss the previous year. This turnaround, supported by collaboration economics, strengthens the company's balance sheet ahead of a key FDA decision for rusfertide in Q3 2026, which is a major short-term catalyst. The article also notes the continued use of employee stock ownership plans, which could impact per-share metrics if not balanced by sustained operating performance.
Protagonist Therapeutics stock hits all-time high at 155.01 USD By Investing.com
Protagonist Therapeutics (PTGX) stock reached an all-time high of $155.01, just shy of its 52-week high, with a market capitalization of $10 billion, representing a 175.66% increase over the past year. This surge is attributed to growing investor confidence and positive developments in its research pipeline, despite InvestingPro analysis suggesting the stock is currently overvalued. The company recently reported strong Q2 2026 GAAP earnings of $2.29 per share and $213 million in license and collaboration revenue, prompting multiple analyst upgrades and increased price targets.
Protagonist Therapeutics stock hits all-time high at 155.01 USD
Protagonist Therapeutics (PTGX) stock reached an all-time high of $155.01, reflecting a 175.66% increase over the past year. The biotechnology firm has a market capitalization of $10 billion and saw a 35% revenue surge in the last twelve months. Despite an InvestingPro analysis suggesting overvaluation, analysts from Goldman Sachs, Citizens, Truist Securities, TD Cowen, and Wolfe Research have issued positive ratings and price target increases based on promising drug developments and prescription volumes.
Farallon group (PTGX) discloses 6.43M-share, warrant‑backed stake in Protagonist
Farallon Capital Management, L.L.C. has disclosed a significant stake in Protagonist Therapeutics (PTGX), reporting beneficial ownership of 6,433,119 shares, which represents 9.99% of the company's outstanding common stock. This ownership includes 6,348,906 direct shares and 1,500,000 common stock purchase warrants, although the warrants are subject to a 9.99% beneficial ownership limitation, restricting the currently exercisable shares from warrants to 84,213. The remaining 1,415,787 warrants are not exercisable within 60 days due to this limitation.
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock
Dinesh V. Patel, CEO of Protagonist Therapeutics (NASDAQ: PTGX), sold approximately $14.9 million worth of company stock on August 10 and 11, 2026. These sales, part of a pre-arranged 10b5-1 trading plan, involved 100,000 shares acquired through stock option exercises at an exercise price of $21.58 per share. The transactions occurred while PTGX stock was trading near its 52-week high, following strong financial results and positive analyst upgrades.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages
Protagonist Therapeutics (NASDAQ:PTGX) has received an average "Moderate Buy" rating from eighteen brokerages, with an average 12-month price target of $137.86. The company recently reported strong quarterly earnings and revenue, exceeding consensus estimates, while its shares trade near their 12-month high. Despite recent insider selling, institutional investors maintain a significant ownership stake, and positive sentiment is driven by FDA approvals and pipeline advancements.
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock
Protagonist Therapeutics CEO Dinesh Patel sold 100,000 shares of the company's common stock for approximately $14.9 million on August 10 and 11, 2026. These sales were part of a pre-arranged 10b5-1 trading plan after exercising stock options at $21.58 per share. The transactions occurred while PTGX stock was near its 52-week high, reflecting significant gains over the past year.
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $5,085,176.28 in Stock
Protagonist Therapeutics CEO Dinesh Ph. Patel sold 34,239 shares of company stock for over $5 million on August 11th, reducing his stake by 6.14% while still holding a significant position. This transaction, made under a pre-arranged trading plan, occurred as PTGX shares rose 2.5% to $152.01, close to its 52-week high. The company recently surpassed quarterly earnings and revenue estimates, maintaining a "Moderate Buy" consensus rating among analysts.
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 65,761 Shares
Protagonist Therapeutics CEO Dinesh Ph Patel sold 65,761 shares of the company's stock for approximately $9.81 million, reducing his stake by 11.16%. The sale occurred under a pre-arranged Rule 10b5-1 plan. Shares rose 2.5% to $152.01 after the company surpassed Q3 earnings and revenue expectations, maintaining a "Moderate Buy" consensus rating from analysts.
Protagonist Therapeutics (PTGX) CEO sells 100,000 shares after option exercise
Protagonist Therapeutics President and CEO Dinesh V. Patel exercised stock options for 100,000 shares at $21.58 each and subsequently sold all 100,000 shares in open-market transactions on August 10-11, 2026. The sales, conducted under a Rule 10b5-1 trading plan, generated approximately $14.89 million in gross proceeds against an exercise cost of $2.16 million. These transactions were related to fully vested options set to expire in October 2026.
Protagonist Therapeutics gains FDA nod for ICOT...
Protagonist Therapeutics has received FDA approval for ICOTYDE to treat moderate-to-severe plaque psoriasis, reinforcing its "Strong Buy" rating. The company is also advancing rusfertide for polycythemia vera, with an FDA Priority Review decision expected by August 2026, and developing PN-881 for psoriasis. These developments are supported by a strong cash reserve of $849.5 million and ongoing royalty streams.
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - Here's Why
Protagonist Therapeutics (NASDAQ:PTGX) recently achieved a new 52-week high of $151.88, closing at $148.29, driven by strong analyst sentiment and exceeding quarterly earnings expectations. The company reported $2.29 EPS against a $2.27 estimate and a significant 3,746.8% year-over-year revenue surge to $213.47 million. Despite insider stock sales, institutional investors have increased their stakes, contributing to a "Moderate Buy" consensus rating and an average price target of $137.86.
PTGX (PTGX) insider files to sell 225,000 shares under Rule 144
An insider at Protagonist Therapeutics (PTGX) has filed to sell 225,000 common shares under Rule 144, with an aggregate market value of $33,583,500. The sale will be executed through J.P. Morgan Securities LLC on Nasdaq and is associated with an option exercise. This filing also noted a previous sale of 75,000 shares on May 12, 2026, for $7,508,850.
Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating
Wedbush has increased its price target for Protagonist Therapeutics (PTGX) to $173 from $118, while maintaining an Outperform rating on the stock. This adjustment reflects a more optimistic outlook from the analyst firm.
PROTAGONIST THERAPEUTICS, INC. : WEDBUSH RAISES TARGET PRICE TO $173 FROM $118
Wedbush has increased its target price for Protagonist Therapeutics, Inc. to $173 from $118. This news was reported by Reuters on August 10, 2026, and indicates a significant upward revision in the analyst's valuation of the company.
Protagonist upgraded at Goldman Sachs on potential of autoimmune asset
Goldman Sachs upgraded Protagonist Therapeutics (PTGX) to a buy rating from neutral, setting a price target of $186. The upgrade is driven by the promising potential of the company's phase 1 oral IL-17 antagonist, PN-881, which is being developed for various autoimmune conditions. This target implies a significant upside of approximately 28% based on the August 7 closing price.
Goldman Sachs Upgrades Protagonist Therapeutics to Buy From Neutral, Adjusts PT to $186 From $110
Goldman Sachs has upgraded Protagonist Therapeutics (PTGX) to a "Buy" rating from "Neutral" and increased its price target to $186 from $110. The article also notes that Protagonist Therapeutics has an average rating of "Buy" and a mean price target of $159.36 from other analysts.
PROTAGONIST THERAPEUTICS, INC. : WEDBUSH RAISES TARGET PRICE TO $173 FROM $118
Wedbush has increased its target price for Protagonist Therapeutics, Inc. to $173, up from the previous $118. The information is provided by Reuters and indicates a significant positive revision in the analyst's outlook for the company's stock.
Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating
Truist has raised its price target for Protagonist Therapeutics (NASDAQ: PTGX) from $145 to $170, while maintaining a "Buy" rating on the stock. This adjustment reflects a continued positive outlook from the firm on the biopharmaceutical company. Other analysts, including Goldman Sachs and Wedbush, also recently upgraded their price targets for Protagonist Therapeutics.
Goldman Sachs upgrades Protagonist Therapeutics stock rating on drug potential
Goldman Sachs upgraded Protagonist Therapeutics (NASDAQ:PTGX) to Buy from Neutral, raising its price target to $186 from $110, citing the potential of its oral IL-17 drug, PN-881. The company recently reported strong Q2 2026 financial results, including significant license and collaboration revenue and a healthy cash position. Analysts are optimistic about PN-881's efficacy, comparing it to Bimzelx, and its commercial potential, with several other firms also adjusting their price targets and ratings upwards.
Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating
Wedbush has increased its price target for Protagonist Therapeutics (PTGX) to $173 from $118, while maintaining an Outperform rating on the stock. This adjustment comes as Protagonist Therapeutics currently holds an average analyst rating of "buy" with a mean price target of $159.36.
Protagonist Therapeutics (PTGX) Swings To Net Income, Is The Valuation Too Expensive?
Protagonist Therapeutics (PTGX) recently reported a swing to net income of US$162.85 million in Q2 2026, leading to significant share price momentum. Despite a high Price-to-Earnings ratio of 113.8x compared to industry averages, driven by strong future earnings growth forecasts, the company's Discounted Cash Flow model suggests the stock is materially undervalued. Investors should consider the potential risks and conduct their own due diligence, as the P/E ratio indicates overvaluation while the DCF model points to undervaluation.
Protagonist Therapeutics (NASDAQ:PTGX) Rating Lowered to Buy at Wall Street Zen
Wall Street Zen has downgraded Protagonist Therapeutics (NASDAQ:PTGX) from a "strong buy" to a "buy" rating. Despite this, the broader analyst consensus remains a "Moderate Buy" with an average price target of $126.71. The company recently reported strong quarterly earnings, beating estimates with $2.29 EPS and revenue up 3,746.8% year-over-year.
Protagonist Therapeutics (PTGX): State Street discloses 5.2% beneficial ownership stake
State Street Corporation has reported a 5.2% passive beneficial ownership stake in Protagonist Therapeutics, Inc., holding 3,321,554 common shares. The filing indicates that State Street exercises shared voting power over 3,157,671 shares and shared dispositive power over all 3,321,554 shares through various investment management subsidiaries. This disclosure was made via a Schedule 13G SEC filing, confirming its role as a parent holding company.
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
Protagonist Therapeutics (PTGX) is showing significant upside potential due to notable revisions in its earnings estimates, reflecting growing optimism from analysts. The company's earnings outlook continues to improve, with current-quarter EPS expected to increase by 446.8% and full-year EPS by 280.0%. This positive trend in estimate revisions has earned PTGX a Zacks Rank #2 (Buy), suggesting potential for continued stock price appreciation.
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics (Nasdaq:PTGX) announced the granting of inducement awards to two new employees on July 31, 2026. These awards, consisting of options to purchase 7,300 shares and restricted stock units for 1,975 shares, were made under the company's Amended and Restated Inducement Plan. The company also highlighted the recent commercial launch of ICOTYDE™ and the priority review status for rusfertide.
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside
Protagonist Therapeutics, Inc. (PTGX) has seen its average 12-month price target raised to $152.14 by 14 analysts, up from $148.93. This updated target suggests an 11% potential upside from the August 5 closing price. The consensus rating for PTGX remains "Buy," with 13 analysts recommending a buy and 1 recommending a hold.
Protagonist Therapeutics (PTGX) Stock Price Surges After Profit Inflection
Protagonist Therapeutics (PTGX) saw its stock price surge after reporting a significant profit inflection in Q2 2026, with revenue reaching US$213.5 million and basic EPS at US$2.47, a major turnaround from previous losses. This shift is largely attributed to the strong performance of ICOTYDE in its first full quarter. While this profitability supports a bullish outlook, questions remain about the sustainability of revenue and earnings, especially given the company's reliance on a narrow set of assets and the upcoming rusfertide decision.
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by California State Teachers Retirement System
The California State Teachers Retirement System increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 22.2% in Q1, now holding 58,677 shares valued at $6.2 million. Despite insider sales totaling $11.5 million in the last 90 days, institutional investors own 98.63% of the company, and analysts maintain a "Moderate Buy" rating with a $123 price target. Protagonist Therapeutics recently reported strong quarterly earnings, beating EPS estimates and achieving a significant year-over-year revenue increase of 3746.8%.
Bank of America Corp DE Has $136.54 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX
Bank of America Corp DE significantly increased its stake in Protagonist Therapeutics, Inc. by 49.3% in the first quarter, now holding 1.30 million shares valued at approximately $136.5 million. This move is part of a broader trend where institutional investors and hedge funds own 98.63% of the company's stock. Despite positive analyst ratings and strong quarterly earnings, company insiders have recently sold a substantial number of shares.
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q2 Revenue $213.5M, Vs. FactSet Est of $199.8M
Protagonist Therapeutics, Inc. (PTGX) announced its Q2 revenue of $213.5 million, surpassing the FactSet estimate of $199.8 million. This report highlights a stronger-than-expected financial performance for the quarter.
Citigroup Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock
Citigroup has raised its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $175 from $130, maintaining a "buy" rating and implying a 19.78% upside. The company recently exceeded quarterly earnings expectations, reporting $2.29 EPS against $2.24 expected, and revenues of $213.47 million. Despite positive analyst sentiment and strong institutional investment, insider selling totaling $11.55 million occurred last quarter.
PROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00
Leerink Partners has increased its target price for Protagonist Therapeutics, Inc. to $150.00, up from the previous $110.00. This adjustment reflects an updated outlook from the financial firm regarding the biotechnology company. The information was reported by Reuters.
Protagonist Therapeutics stock hits all-time high at 143.43 USD
Protagonist Therapeutics (PTGX) stock has reached an all-time high of $143.43, reflecting strong investor confidence and a 155% return over the past year. The biotech firm, with an $8.83 billion market cap, is projected to see significant revenue growth and profitability by 2026, despite being considered overvalued by InvestingPro data. Analysts have raised price targets based on strong performance of its drug Icotyde and upcoming data for PN-881.
PTGX Maintained by Barclays -- Price Target Raised to $153
Barclays has maintained an "Overweight" rating on Protagonist Therapeutics (PTGX), increasing its price target to $153 from $151. Despite this cautious optimism from analysts, Protagonist Therapeutics is considered significantly overvalued with a GF Value of $72.54 against its current price of $144.87, and insider activity shows substantial selling. The company's GF Score of 47/100 highlights strong financial strength but weak profitability and growth, suggesting investors should proceed with caution.
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Protagonist Therapeutics reported strong second-quarter 2026 financial results, driven by the successful commercial launch of ICOTYDE and significant progress in its R&D pipeline. The company achieved a net income of $162.8 million and increased its cash, cash equivalents, and marketable securities to $849.5 million. Key milestones include the priority review of rusfertide's NDA, planned initiation of a Phase 2b program for PN-881, and a Phase 1 study for PN-477sc in obesity.
Protagonist Therapeutics stock hits all-time high at 143.43 USD By Investing.com
Protagonist Therapeutics (PTGX) stock reached an all-time high of $143.43, marking a 155% 1-year return. Despite an $8.83 billion market cap, InvestingPro suggests the stock may be overvalued relative to its Fair Value. Analysts project significant revenue growth and profitability by 2026, with several firms raising price targets due to strong performance and product potential like Icotyde.
PROTAGONIST THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $175 FROM $130
Citigroup has raised its target price for Protagonist Therapeutics, Inc. to $175 from $130. This update indicates a significant increase in the analyst's valuation of the company. The article, sourced from Reuters, briefly notes this financial adjustment.
Protagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary
Protagonist Therapeutics, Inc reported significantly increased revenue of $213.48M and diluted EPS of $2.29 for the 2026 quarter, largely due to license and collaboration revenue from a Takeda opt-out payment and a J&J milestone. The company achieved a net income of $162.85M compared to a loss in the prior year. Key business highlights include the U.S. approval of ICOTYDE, the acceptance of the Rusfertide NDA with Priority Review, and advancements in its R&D pipeline, leading to a strong cash balance of $849.5M.
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Protagonist Therapeutics, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is available on TradingView, sourced from Refinitiv and Reuters.
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
Protagonist Therapeutics (PTGX) reported Q2 earnings of $2.29 per share, significantly beating the Zacks Consensus Estimate of $2.11 and reversing a loss from the prior year. Despite missing revenue estimates for the quarter, the company's shares have risen 55.5% year-to-date. The stock currently holds a Zacks Rank #2 (Buy), indicating potential for market outperformance.
Protagonist Therapeutics (NASDAQ: PTGX) turns Q2 2026 loss into profit
Protagonist Therapeutics (NASDAQ: PTGX) reported a significant financial turnaround in Q2 2026, shifting from a loss to a net income of $162.8 million and diluted earnings per share of $2.29. This was primarily driven by approximately $213.5 million in license and collaboration revenue, including a $192.4 million opt-out payment recognition from Takeda and a $50 million milestone from Johnson & Johnson. The company also highlighted key pipeline advancements, including the full commercial quarter for ICOTYDE and the FDA priority review for rusfertide with an August 2026 PDUFA date, all supporting a non-dilutive funding model.
PTGX|Protagonist Therapeutics Inc|Price:132.170|Chg%:-4.470
This article provides an in-depth analysis of Protagonist Therapeutics Inc. (PTGX), covering its market trends, real-time quotes, and related analysis. It highlights the company's strong fundamentals and growth potential, despite a recent turnaround to loss, and offers a comprehensive look at its financial indicators, analyst ratings, and peer comparisons.
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics (Nasdaq:PTGX) announced that on July 31, 2026, it granted inducement awards to two new employees. These awards, consisting of options to purchase 7,300 shares and 1,975 Restricted Stock Units (RSUs), were made under the company's Amended and Restated Inducement Plan. The grants were approved by the compensation committee and serve as a material inducement for the employees' new employment.
